Counterfeiter of Tagamet, Naprosyn sentenced
Executive Summary
On May 7, in Los Angeles Federal Court Javid Naghdi was sentenced to 14 years of incarceration for "his scheme to sell millions of counterfeit drugs," according to FDA's March/April Case News. In 1987, he and three others (the "Naghdi Group") were convicted of selling counterfeit Naprosyn, but Naghdi fled the country before being sentenced ("The Pink Sheet" Sept. 14, T&G-9). He was later apprehended, extradited and sentenced to five years in jail. Naghdi was then "tried and convicted on nine counts of wire fraud for offering one million bottles of Tagamet to an undercover agent for $28 mil."
You may also be interested in...
FDA Authorizes Athletic Collar To Reduce Brain Injuries
The Q-Collar is meant to work by improving blood flow to the brain, and has been shown to reduce signs of trauma from head impacts when playing sports.
Ad Hominis: FDA Authorizes Memic Innovative’s Surgical Robot
The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.
BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A
Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: